旨在评估程序性死亡 1 (PD-1) 抑制剂与重组人内皮抑素联合治疗晚期非小细胞肺癌 (NSCLC) 患者的治疗效果。我们回顾性收集了 83 名接受治疗的晚期 NSCLC 患者的数据2020年5月至2022年7月在西安大兴医院进行的检查。其中，42例患者接受PD-1抑制剂联合重组人内皮抑素治疗（观察组），41例患者接受PD-1抑制剂单药治疗（对照组）。我们评估了两组的客观缓解率、治疗前后血清肿瘤标志物的变化、不良反应的发生情况、无进展生存期（PFS）、1年生存率，并确定影响预后的独立危险因素。观察组治疗效果明显优于对照组。治疗后，观察组细胞角蛋白19片段抗原21-1、癌胚抗原、糖类抗原125水平较对照组显着降低（P < 0.001）。两组不良反应发生率无显着性差异（P<0.001）。观察组的中位 PFS 和 1 年生存率显着较高（P < 0.001）。年龄、肝转移和治疗方案成为影响患者不良预后的独立危险因素（P < 0.001）。PD-1抑制剂与重组人内皮抑素联合治疗晚期NSCLC患者不仅可以提高临床疗效，而且可以提高PFS和患者生存率。 1年生存率同时保证治疗安全。这种联合疗法显示出临床应用的前景。AJTR 版权所有 © 2024。

To assess the therapeutic efficacy of combining a programmed death-1 (PD-1) inhibitor with recombinant human endostatin in patients diagnosed with advanced non-small cell lung cancer (NSCLC).We retrospectively collected data from 83 patients with advanced NSCLC who received treatment at Xi'an Daxing Hospital between May 2020 and July 2022. Among them, 42 patients were treated with a PD-1 inhibitor combined with recombinant human endostatin (observation group), while 41 patients received PD-1 inhibitor monotherapy (control group). We evaluated the objective response rate, changes in serum tumor markers pre- and post-treatment, occurrence of adverse reactions, progression-free survival (PFS), 1-year survival rate, and identified independent risk factors affecting prognosis in both groups.The treatment efficacy in the observation group significantly surpassed that in the control group. Following treatment, the levels of cytokeratin 19 fragment antigen 21-1, carcinoembryonic antigen, and carbohydrate antigen 125 decreased significantly in the observation group compared to the control group (P < 0.001). There was no notable difference in the incidence of adverse reactions between the two groups (P < 0.001). The median PFS and 1-year survival rate were notably higher in the observation group (P < 0.001). Age, liver metastasis, and treatment regimen emerged as independent risk factors affecting poor prognosis in patients (P < 0.001).Combining a PD-1 inhibitor with recombinant human endostatin in patients with advanced NSCLC not only enhances clinical efficacy but also increases PFS and the 1-year survival rate while ensuring treatment safety. This combination therapy shows promise for clinical application.AJTR Copyright © 2024.